Sign In
Buy DXCM
$72.77
-0.680 (-0.93%)
At Close: Jun 03, 2026
If You'd Invested $1,000 in DexCom 10 Years Ago, Here's How Much You'd Have Today
08:21am, Friday, 29'th Aug 2025
Shares of DexCom (DXCM 0.02%), a medical device specialist, have lagged the market this year. However, the true test of a company isn't how it performs over a relatively short period, such as eight mo
Dexcom Announces Upcoming Conference Presentations
08:30am, Tuesday, 26'th Aug 2025
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences: The 2025 Wells Fargo Health
DexCom Expands Access and Innovation While Balancing Headwinds
12:21pm, Wednesday, 20'th Aug 2025
DXCM grows on type 2 access, Stelo adoption, and new sensor launches, but faces margin pressures, competition and leadership transition.
2 Stocks to Buy on the Dip and Hold for 10 Years
05:30am, Saturday, 16'th Aug 2025
Despite President Donald Trump's trade wars and concerns about a possible recession, equity markets have performed relatively well this year, with the S&P 500 (^GSPC -0.29%) up 10% since January. Some
NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DexCom, Inc. (NASDAQ: DXCM) on b
Dexcom's Arizona facility can service good portion of U.S. business, says CEO
03:00pm, Tuesday, 05'th Aug 2025
CNBC's "The Exchange" team discusses the potential of tariffs on pharmaceuticals, U.S. manufacturing and more with Dexcom CEO and chairman Kevin Sayer.
DexCom (DXCM) Q2 Revenue Jumps 15%
12:53am, Friday, 01'st Aug 2025
DexCom (DXCM) Q2 Revenue Jumps 15%
DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise
09:51am, Thursday, 31'st Jul 2025
DXCM beats on Q2 earnings and raises 2025 sales guidance, but shares dip as margin pressure dampens investor enthusiasm.
DexCom, Inc. (DXCM) Q2 2025 Earnings Call Transcript
08:58pm, Wednesday, 30'th Jul 2025
DexCom, Inc. (NASDAQ:DXCM ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Jacob Steven Leach - President & COO Jereme M. Sylvain - Executive VP, CFO & Chief Accounting
Compared to Estimates, DexCom (DXCM) Q2 Earnings: A Look at Key Metrics
07:01pm, Wednesday, 30'th Jul 2025
Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street es
DexCom (DXCM) Q2 Earnings and Revenues Top Estimates
06:16pm, Wednesday, 30'th Jul 2025
DexCom (DXCM) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.43 per share a year ago.
Dexcom beats estimates for quarterly results, names new CEO
05:23pm, Wednesday, 30'th Jul 2025
Dexcom beat estimates for second-quarter results on Wednesday, driven by strong demand for its continuous glucose monitors, and named Jake Leach as its CEO.
Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan
04:02pm, Wednesday, 30'th Jul 2025
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan.
Ontario Expands Access to Dexcom G7 CGM Under the Ontario Drug Benefit (ODB) Program
08:00am, Wednesday, 30'th Jul 2025
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Ontario government for its recent decision to include the Dexcom G7 Continu
DexCom (DXCM) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
01:06am, Tuesday, 29'th Jul 2025
Besides Wall Street's top-and-bottom-line estimates for DexCom (DXCM), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quar
